Navigation Links
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
Date:12/4/2008

First Selective TLR8 Agonist to Advance to Clinical Trials

SAN DIEGO, Dec. 4 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and autoimmune diseases, announced today that it has initiated a Phase I clinical trial of VTX-2337, a selective TLR8 agonist for the treatment of cancer. The multi-center clinical trial is being conducted at the Mayo Clinic Arizona and TGen Drug Development Services (TD2) both in Scottsdale, Arizona.

"We are delighted to advance the first molecule from our Toll-Like Receptor 8 platform, VTX-2337, into the clinic," said Michael Kamdar, Executive Vice President and Chief Business Officer at VentiRx. "This represents a significant milestone for VentiRx and our TLR efforts as we have rapidly advanced into a clinical development company with a novel molecule that may have broad application in the treatment of cancer."

VTX-2337 is a small molecule TLR8 agonist that is expected to be used in combination with standard of care for the treatment of patients with cancer. Preclinical evaluation of VTX-2337 suggests that it may play a key role in augmenting the innate arm of the immune system and provide a valuable addition to various treatment regimens in oncology. The first clinical trial will investigate the safety and pharmacology of multiple doses of VTX-2337 in patients with late stage cancer.

"VTX-2337 is the first selective TLR8 compound to reach the clinic and we are hopeful that modulation of the innate immune response will provide a benefit to patients in a number of oncology indications," said Dr. Robert Hershberg, Executive Vice President and Chief Medical Officer at VentiRx.

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals, Inc. is a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer, respiratory and autoimmune diseases. The Company's initial focus is on developing small molecule TLR-based product candidates for oncology and allergy. VentiRx is a privately held organization headquartered in San Diego with operations in Seattle. For additional information, please visit www.ventirx.com.


'/>"/>
SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... -- ivWatch, a medical devices company, is one of five recipients ... Terry McAuliffe,s office. ivWatch will be receiving the ... event to be held at the Science Museum of ... business that have made significant contributions to science. ... ...
(Date:2/5/2016)... -- Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion of ... Canada Inc. ("Tribute") following approval of the transaction by ... company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), a ... Canada , Ireland and ... terms of the Agreement and Plan of Merger and ...
(Date:2/5/2016)... Feb. 5, 2016  Venice,s newest laser clinic, ... first of its kind in the area and ... advanced laser treatment. The physician-owned and operated laser ... Suncoast by storm with its revitalizing skin care ... multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... , ... Delta Dental of California and its affiliated companies announced today that ... who recently retired as president and CEO of Delta Dental of California and its ... Year , helped lead the effort to raise funds for studies to strengthen pancreatic ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain ... 1,400 booths and 700 companies. Attendees also get to see the most incredible ... Garden & Home Show , at the Colorado Convention Center - 700 14th St. ...
(Date:2/8/2016)... ... ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated personal growth ... on February 10th. During this time, people can achieve better health, greater wealth, ... from over 40 different countries as an “ordinary man with an extraordinary gift.” ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart ... employers and organizations with the tools and information to lower the costs, and ... cut the cost of providing employee healthcare benefits by as much as 22%:, ...
(Date:2/6/2016)... , ... February 06, 2016 , ... Shark Finds ... announce the launch of a new DRTV campaign with Belly Bands. , Having a ... everything from sprays to puppy pads and find nothing works, get Belly Bands, ...
Breaking Medicine News(10 mins):